Nachrichten zur Eli Lilly & Co Aktie

2 Stocks That Could Soar Again in 2025

Many companies in the biotech industry performed well last year. Two in particular stood out: Viking Therapeutics (NASDAQ: VKTX) and…

Lilly Endowment sells $183.6 million in Eli Lilly stock By Investing.com

Lilly Endowment sells $183.6 million in Eli Lilly stock…

Eli Lillys rating gets an upgrade to Aa3 by Moodys Ratings By Investing.com

Eli Lillys rating gets an upgrade to Aa3 by Moodys Ratings…

Lilly expands GLP-1 research to hypertension, neuro conditions

Morning. Today, we have a look at the White Houses reported plans to make major cuts across federal health agencies.…

Eli Lilly Q4: Dont Miss Out On 2025 Gains, Theres Limited Space Left

…

Eli Lilly (LLY) Q4 2024 Earnings Call Transcript

LLY earnings call for the period ending December 31, 2024.…

Eli Lilly has its mojo back ahead of a pivotal year for the obesity drug giant

The drugmaker is not perfect, as the past few months showed, but its still a thoroughbred.…

Why Eli Lilly Stock Popped on Thursday

Eli Lilly (NYSE: LLY) stock inched 2.5% higher through 9:50 a.m. ET Thursday after beating on the top and bottom…

LLYs Q4 Earnings Beat, Mounjaro, Zepbound Sales Fall Shy of Estimates

Eli Lilly beats fourth-quarter estimates for earnings and sales. Mounjaro and Zepbound sales miss estimates.…

Eli Lilly to release late-stage data on next-generation weight loss drug retatrutide in 2025, earlier than expected

Eli Lilly expects to provide results from a study in people with obesity and osteoarthritis of the knee in 2025.…

Stocks making the biggest moves premarket: Ford, Eli Lilly, Honeywell, Arm Holdings and more

These are the stocks posting the largest moves in premarket trading.…

Eli Lilly beats on earnings even as weight loss, diabetes drug sales fall short

Zepbound and Mounjaro have now underperformed expectations for two straight quarters.…

Diabetes and obesity drugs fuel Eli Lilly profit in the final quarter of 2024

…

Eli Lilly reports mixed earnings, increases 2025 guidance

…

Pharmakonzern Lilly beendet 2024 überraschend stark - Prognose bestätigt

INDIANAPOLIS (dpa-AFX) - Ein florierendes Geschäft mit seinen Diabetes- und Abnehmmitteln hat dem US-Pharmahersteller Lilly 2024…

Lilly forecasts 2025 profit largely above estimates on weight-loss drug strength

Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, banking on the launch of its popular diabetes…

Eli Lilly Q4 earnings beat as weight loss drug sales miss estimates

Eli Lilly and Co (NYSE:LLY) reported mixed results for the fourth quarter, with earnings outpacing estimates as revenue from its…

Eli Lilly revenue misses expectations despite strong growth in Mounjaro, Zepbound

Eli Lilly and Co (NYSE:LLY) reported mixed results for the fourth quarter, with earnings outpacing estimates despite revenue from its…

Stock futures are little changed after S&P 500 posts back-to-back winning sessions: Live updates

Following a second day of stock market gains, investors looked forward to earnings reports from Eli Lilly and Amazon.…

Eli Lilly must put to rest doubts about whether Zepbounds growth can live up to the hype

Living up to the hype around GLP-1 obesity treatments is tough enough. But Eli Lilly needs to hit its own…

Why Novo Nordisk Stock Is Soaring Today

Shares of Novo Nordisk (NYSE: NVO) were moving higher on Wednesday. The companys stock gained 4.9% as of 1:50 p.m.…

Lilly needs a plan to spur weight-loss drug sales, investors say

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to…

Novo Nordisk Q4 profit beats expectations, sees slower growth in 2025

Wegovy maker Novo Nordisk on Wednesday forecast slower sales growth for 2025 than 2024, a blow that is likely to…

The Zacks Analyst Blog Highlights Merck, Pfizer, Eli Lilly, Amgen and Bristol Myers Squibb

Merck, Pfizer, Eli Lilly, Amgen and Bristol Myers Squibb are included in this Analyst Blog.…

3 Magnificent Stocks to Buy and Hold Forever

Some people are fair-weather friends; others are lifelong. Its a similar story with stocks. Some you might hold only temporarily,…

Eli Lilly Stock Before Q4 Earnings: To Buy or Not to Buy?

Investor focus is likely to be on the sales numbers of LLYs tirzepatide medicines Mounjaro and Zepbound.…

Here are the 11 things were watching in the stock market in the week ahead

Jobs data and earnings from the likes of Amazon and Eli Lilly take center stage in the week ahead.…

Forget Wegovy: Novo Nordisk May Have a New Billion-Dollar Weight Loss Drug On Its Hands

Drugmakers have poured small fortunes into the development of weight loss medicines in the past few years in attempts to…

With Zepbound Not Matching Expectations, Should Investors Give Up on Eli Lilly?

Over the past six months, Eli Lilly (NYSE: LLY) has underperformed broader equities. While thats not much of an issue…

Got $1,000? 2 Top Growth Stocks to Buy Right Now

Being a long-term investor isnt always easy, as youll inevitably encounter downturns as well as the thriving bull periods that…

3 Unstoppable Stocks You Can Buy and Hold for the Rest of Your Life

If you want stocks that you can buy and hold for not only years, but potentially the rest of your…

Jim Cramers week ahead: Earnings from Amazon, Alphabet, Eli Lilly, Palantir

CNBCs Jim Cramer on Friday walked investors through an earnings-heavy week.…

Eli Lilly CEO Hasn’t Bought Company Shares in Years. He Just Bought This Stock.

…

Wafaa Mamilli To Join Roche As Chief Digital Technology Officer

Wafaa Mamilli will join Roche as the companys new Chief Digital Technology Officer in February. This follows expansive roles she…

A mixed bag on Day 2 of the DeepSeek shock, plus Eli Lilly keeps its win streak alive

Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of…

Got $5,000? 2 Top Healthcare Stocks to Buy in 2025 and Hold Forever.

Some people make it a New Years resolution to improve their finances by investing in stocks. Its a laudable goal,…

Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It. @themotleyfool #stocks $LLY

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has…

dpa-AFX ProFeed